Skip to main content

Coronavirus (COVID-19) Updates: Visitation Policies (New! 11.25.20) | How We're Keeping You Safe | Latest COVID Information

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

ILYM17064 / RSRB70432 / Paul Barr

Research Question:
What is the safety and efficacy of a new investigational combination of drugs venetoclax in combination with Ublituximab and Umbralisib (TGR-1202)) that have not been tried before?

Basic Study Information

Purpose:
Phase I/II Study of Venetoclax in Combination with Ublituximab and Umbralisib (TGR-1202) in Subjects with Relapsed or Refractory CLL/SLL, Richter's Transformation and Mantle Cell Lymphoma

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03379051?term=venetoclax+in+combination+with+Ublituximab&rank=1
Study Reference #: ILYM17064

Lead Researcher (Principal Investigator)

Lead Researcher:  Paul Barr

Study Contact Information

Study Coordinator: Amber Johnson
Email: amber_johnson@urmc.rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Lymphoid leukemia, chronic

Return to Search